Samira, a breast cancer survivor and CEO of Manta Cares, discusses the latest advancements in cancer treatment with Dr. Doug Blayney at the ASCO conference. They explore the significant impact of exercise on cancer treatment tolerance and survival, the de-escalation of chemotherapy, the introduction of new therapies like SERDs and antibody drug conjugates, and the role of circulating tumor DNA in monitoring cancer recurrence. The conversation emphasizes the importance of patient convenience and self-advocacy in cancer care.
About Our Guest:
Douglas W. Blayney, MD is a Professor of Medicine (Oncology), Emeritus, former Medical Director of Stanford Cancer Center, and specializes in the treatment of breast cancer. He has a special interest in the quality and value of cancer care. Dr. Blayney is a past president of the American Society of Clinical Oncology (ASCO), a founder of the ASCO Quality Symposium, a co-author of the ASCO value framework descriptions, and instigated the ASCO clinical "big data" effort, which is now CancerLinQ. He received the inaugural Ellen Stovall Award for Leadership in Patient Centered Care from the National Coalition for Cancer Survivorship in 2016. He was previously a Professor of Internal Medicine and Medical Director of the Comprehensive Cancer Center at the University of Michigan, and prior to that practiced and led Wilshire Oncology Medical Group, Inc. a physician owned multidisciplinary oncology practice in southern California. He has expertise on clinical trial development, use of oncology drugs in clinical practice, reimbursement and marketing strategies and information technology use.
Chapter Codes
00:00 The Impact of Exercise on Cancer Treatment
02:00 Interview at ASCO Starts
06:00 Advancements in Cancer Treatment: De-escalation and AI
11:52 Emerging Therapies: SERDs and Antibody Drug Conjugates
18:11 Circulating Tumor DNA: A New Frontier in Monitoring
24:01 Convenience in Cancer Care: A Patient-Centric Approach
Takeaways
- Regular exercise can increase tolerance to cancer treatments.
- Data shows exercise has tangible benefits on survival rates.
- De-escalation of chemotherapy is a key focus in cancer treatment.
- AI is being integrated into cancer treatment guidelines.
- Patients can take proactive steps to improve their health.
- Oral SIRDs are emerging as a more convenient treatment option.- Antibody drug conjugates target cancer cells with fewer side effects.
- Circulating tumor DNA can help detect cancer recurrence earlier.
- Convenience in treatment is becoming a priority for patients.
- Competition among treatments may help reduce costs for patients.
Tags & Keywords:
cancer treatment, ASCO, exercise, AI, SIRDs, antibody drug conjugates, circulating tumor DNA, patient care, chemotherapy, cancer survival, health technology
Connect with Us:
Enjoyed this episode? Make sure to subscribe, rate, and review! Follow us on Instagram, Facebook, or Linkedin @mantacares and visit our website at mantacares.com for more episodes and updates.
Listen Elsewhere:
Website: https://mantacares.com/pages/podcast?srsltid=AfmBOopEP5GJ-Wd2nL-HYAInrwerIVhyJw67salKT-r9Qb_gadBvbHie YouTube: https://youtu.be/UjsAtpbedA8 Spotify: https://open.spotify.com/episode/7HwhjXHZU0ZWWVkXrCSV7V?si=d5e986f0885a4bbb Apple: https://podcasts.apple.com/us/podcast/cervical-cancer-and-hpv-what-you-need-to-know/id1622669098?i=1000710235401
Disclaimer:
All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.